Form 4: Editas Medicine CSO Sells Shares for Tax Obligations

Editas Medicine's EVP and Chief Scientific Officer, Linda Burkly, sold 710 shares of common stock at $2.5961 per share to cover tax withholding obligations from restricted stock unit vesting.

Summary

• Linda Burkly, Executive Vice President and Chief Scientific Officer of Editas Medicine, Inc. (EDIT), reported a sale of common stock.
• The transaction involved the disposition of 710 shares of common stock at a price of $2.5961 per share on September 3, 2025.
• This sale was non-discretionary, executed under a Rule 10b5-1 plan adopted on July 3, 2023.
• The purpose of the sale was to meet tax withholding obligations resulting from the vesting of restricted stock units on September 2, 2025.
• Following this transaction, Linda Burkly beneficially owns 69,490 shares of Editas Medicine common stock, which includes 5,802 shares acquired under the company's Employee Stock Purchase Plan.

Sentiment

Score: 6

Explanation: The transaction is a routine, non-discretionary sale for tax purposes, which is generally viewed as neutral. It does not indicate a change in the executive's confidence in the company, and a substantial number of shares are still held.

Positives

• The sale was non-discretionary and pre-planned under a Rule 10b5-1 plan, indicating it was a routine event for tax purposes rather than a reflection of a change in management's outlook.
• The executive continues to hold a substantial number of shares (69,490) in the company, demonstrating continued alignment with shareholder interests.

Negatives

• An executive selling shares, even for tax purposes, reduces their direct ownership in the company.
• The sale price of $2.5961 per share is relatively low, which might reflect current market valuation for the company's stock.

Future Outlook

NA

Management Comments

• The sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 3, 2023, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on September 2, 2025. The sale does not represent a discretionary trade by the Reporting Person.

Industry Context

NA

Comparison to Industry Standards

• Tax-related sales under Rule 10b5-1 plans are a common practice among executives in publicly traded companies across various industries, including biotechnology, to manage equity compensation and tax liabilities in a compliant manner.

Stakeholder Impact

• Shareholders: The sale represents a minor reduction in insider ownership, but its non-discretionary nature mitigates concerns about management's confidence. The overall impact on the company's stock price is likely minimal due to the routine nature and small volume relative to total shares outstanding.

Key Dates

Recommendation

The transaction is a non-discretionary sale of shares by a key executive to cover tax withholding obligations arising from the vesting of restricted stock units, executed under a pre-arranged Rule 10b5-1 plan. This is a routine event and does not reflect a change in the executive's confidence in the company or its future prospects. Therefore, it does not provide a basis for a change in investment recommendation.

Keywords

Editas Medicine, EDIT, Linda Burkly, Form 4, Insider Transaction, Stock Sale, Tax Withholding, Restricted Stock Units, 10b5-1 Plan, Biotechnology, Gene Editing